Kovitz Investment Group Partners
GSK icon

Kovitz Investment Group Partners’s GSK GSK Stock Holding History

Kovitz Investment Group Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,869
Closed -$1.07M – 807
2025
Q3 		$1.07M Buy
24,869
+2,875
+13% +$112K ﹤0.01% 830
2025
Q2 		$845K Sell
21,994
-1,292
-6% -$49.4K ﹤0.01% 840
2025
Q1 		$902K Buy
23,286
+1,706
+8% +$62.5K ﹤0.01% 767
2024
Q4 		$730K Buy
21,580
+1,556
+8% +$56K ﹤0.01% 796
2024
Q3 		$718K Buy
20,024
+6,383
+47% +$261K 0.01% 699
2024
Q2 		$525K Sell
13,641
-1,948
-12% -$81.9K ﹤0.01% 647
2024
Q1 		$668K Buy
+15,589
New +$643K 0.01% 464

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kovitz Investment Group Partners's GSK Position: Q4 2025 in Review

Kovitz Investment Group Partners sold out of GSK (GSK) in Q4 2025, closing a stake of 24,869 shares — an estimated $1.07M sold.

Kovitz Investment Group Partners first reported a position in GSK in Q1 2024 and held it in 7 quarters. The position peaked at $1.07M in Q3 2025. 996 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

  • Kovitz Investment Group Partners reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 24,869 GSK shares in Q4 2025, an estimated $1.07M.
  • Kovitz Investment Group Partners first reported a position in GSK in Q1 2024 and held it in 7 quarters.
  • Kovitz Investment Group Partners's GSK position peaked at $1.07M in Q3 2025.
  • 996 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q4 2025, filed 20 Feb 2026.